{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:44Z","timestamp":1772166284184,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02654-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:47:49Z","timestamp":1759236469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fiducial tracking fidelity in robotic prostate SBRT: a comparison of a 3-fraction boost following pelvic nodal irradiation and definitive 5-fraction treatment"],"prefix":"10.1186","volume":"20","author":[{"given":"Jonathan W.","family":"Lischalk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianca F.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Vizcaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andwele","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Clancey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Niglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"2654_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","volume":"84","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):125\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.11.047.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2654_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0167-8140(03)00078-1","volume":"67","author":"H Dehnad","year":"2003","unstructured":"Dehnad H, Nederveen AJ, van der Heide UA, van Moorselaar RJA, Hofman P, Lagendijk JJW. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2003;67(3):295\u2013302. https:\/\/doi.org\/10.1016\/s0167-8140(03)00078-1.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"10","key":"2654_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"issue":"10196","key":"2654_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet Lond Engl. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet Lond Engl"},{"key":"2654_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fonc.2014.00369","volume":"4","author":"D Freeman","year":"2014","unstructured":"Freeman D, Dickerson G, Perman M. Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. Front Oncol. 2014;4:369. https:\/\/doi.org\/10.3389\/fonc.2014.00369.","journal-title":"Front Oncol"},{"key":"2654_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000322507","volume":"43","author":"C King","year":"2011","unstructured":"King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol. 2011;43:428\u201337. https:\/\/doi.org\/10.1159\/000322507.","journal-title":"Front Radiat Ther Oncol"},{"key":"2654_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2011.00049","volume":"1","author":"AJ Katz","year":"2011","unstructured":"Katz AJ, Santoro M, Ashley R, Diblasio F. Stereotactic body radiation therapy for Low- and Low-Intermediate-Risk prostate cancer: is there a dose effect?? Front Oncol. 2011;1:49. https:\/\/doi.org\/10.3389\/fonc.2011.00049.","journal-title":"Front Oncol"},{"issue":"2","key":"2654_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, et al. Multicenter trial of stereotactic body radiation therapy for Low- and Intermediate-Risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102(2):296\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2654_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fonc.2011.00048","volume":"1","author":"S Lei","year":"2011","unstructured":"Lei S, Piel N, Oermann EK, et al. Six-Dimensional correction of Intra-Fractional prostate motion with cyberknife stereotactic body radiation therapy. Front Oncol. 2011;1:48. https:\/\/doi.org\/10.3389\/fonc.2011.00048.","journal-title":"Front Oncol"},{"issue":"5","key":"2654_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/s0360-3016(03)00328-6","volume":"56","author":"MM Poggi","year":"2003","unstructured":"Poggi MM, Gant DA, Sewchand W, Warlick WB. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys. 2003;56(5):1248\u201351. https:\/\/doi.org\/10.1016\/s0360-3016(03)00328-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2654_CR11","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.ijrobp.2005.01.005","volume":"62","author":"PA Kupelian","year":"2005","unstructured":"Kupelian PA, Willoughby TR, Meeks SL, et al. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys. 2005;62(5):1291\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.01.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2654_CR12","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.ijrobp.2012.02.016","volume":"84","author":"DA Tiberi","year":"2012","unstructured":"Tiberi DA, Carrier JF, Beauchemin MC, Nguyen TV, B\u00e9liveau-Nadeau D, Taussky D. Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(1):e7\u201312. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.02.016.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2654_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fonc.2017.00005","volume":"7","author":"I Paydar","year":"2017","unstructured":"Paydar I, Pepin A, Cyr RA, et al. Intensity-Modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: A report on 3-Year toxicity. Front Oncol. 2017;7:5. https:\/\/doi.org\/10.3389\/fonc.2017.00005.","journal-title":"Front Oncol"},{"key":"2654_CR14","doi-asserted-by":"publisher","first-page":"1325200","DOI":"10.3389\/fonc.2024.1325200","volume":"14","author":"JW Lischalk","year":"2024","unstructured":"Lischalk JW, Akerman M, Repka MC, et al. High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation. Front Oncol. 2024;14:1325200. https:\/\/doi.org\/10.3389\/fonc.2024.1325200.","journal-title":"Front Oncol"},{"issue":"1","key":"2654_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2010.10.026","volume":"82","author":"S Jabbari","year":"2012","unstructured":"Jabbari S, Weinberg VK, Kaprealian T, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012;82(1):228\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.10.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2654_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2654_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13014-019-1373-2","volume":"14","author":"N Scher","year":"2019","unstructured":"Scher N, Bollet M, Bouilhol G, et al. Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking. Radiat Oncol. 2019;14(1):167. https:\/\/doi.org\/10.1186\/s13014-019-1373-2.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2654_CR18","first-page":"217","volume":"5","author":"OE Holmes","year":"2018","unstructured":"Holmes OE, Gratton J, Szanto J, et al. Reducing errors in prostate tracking with an improved fiducial implantation protocol for cyberknife based stereotactic body radiotherapy (SBRT). J Radiosurg SBRT. 2018;5(3):217\u201327.","journal-title":"J Radiosurg SBRT"},{"issue":"5","key":"2654_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","volume":"97","author":"DA Hamstra","year":"2017","unstructured":"Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.024.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2654_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.meddos.2017.07.002","volume":"42","author":"RT Jones","year":"2017","unstructured":"Jones RT, Hassan Rezaeian N, Desai NB, et al. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Med Dosim Off J Am Assoc Med Dosim. 2017;42(4):341\u20137. https:\/\/doi.org\/10.1016\/j.meddos.2017.07.002.","journal-title":"Med Dosim Off J Am Assoc Med Dosim"},{"key":"2654_CR21","doi-asserted-by":"publisher","first-page":"860848","DOI":"10.3389\/fonc.2022.860848","volume":"12","author":"MC Repka","year":"2022","unstructured":"Repka MC, Creswell M, Lischalk JW, et al. Rationale for utilization of hydrogel rectal spacers in dose escalated SBRT for the treatment of unfavorable risk prostate Cancer. Front Oncol. 2022;12:860848. https:\/\/doi.org\/10.3389\/fonc.2022.860848.","journal-title":"Front Oncol"},{"issue":"2","key":"2654_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acm2.12051","volume":"18","author":"SG Hedrick","year":"2017","unstructured":"Hedrick SG, Fagundes M, Robison B, et al. A comparison between hydrogel spacer and endorectal balloon: an analysis of intrafraction prostate motion during proton therapy. J Appl Clin Med Phys. 2017;18(2):106\u201312. https:\/\/doi.org\/10.1002\/acm2.12051.","journal-title":"J Appl Clin Med Phys"},{"key":"2654_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1748-717X-9-186","volume":"9","author":"M Sumila","year":"2014","unstructured":"Sumila M, Mack A, Schneider U, Storelli F, Curschmann J, Gruber G. Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife\u00ae treatment for prostate cancer\u2013a case report. Radiat Oncol Lond Engl. 2014;9:186. https:\/\/doi.org\/10.1186\/1748-717X-9-186.","journal-title":"Radiat Oncol Lond Engl"},{"issue":"7","key":"2654_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3109\/0284186X.2015.1128118","volume":"55","author":"C Picardi","year":"2016","unstructured":"Picardi C, Rouzaud M, Kountouri M, et al. Impact of hydrogel spacer injections on interfraction prostate motion during prostate cancer radiotherapy. Acta Oncol Stockh Swed. 2016;55(7):834\u20138. https:\/\/doi.org\/10.3109\/0284186X.2015.1128118.","journal-title":"Acta Oncol Stockh Swed"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02654-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02654-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:03:29Z","timestamp":1759280609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02654-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2654"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02654-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5567210\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single institutional review of patients was approved by the local Institutional Review Board of NYU (Study # 00001269).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jonathan Lischalk is a paid speaker and consultant to Accuray. Jonathan Haas is a paid consultant for Accuray.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Annual ESTRO Congress: May 12, 2023 \u2013 May 16, 2023.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}}],"article-number":"145"}}